Iran Conflict: The Hidden Biological Weapons Threat to US Security
The ongoing conflict in Iran has understandably focused global attention on the risks of nuclear escalation and disruptions to oil supplies. However, a less discussed, yet potentially far more devastating, danger has come into sharper focus: the possibility of biological weapons. Whereas the world grapples with the immediate consequences of military strikes and geopolitical maneuvering, experts are raising concerns about the security of Iran’s biological capabilities and the potential for accidental or deliberate release of dangerous pathogens.
A Longstanding Concern
The U.S. Government has maintained for several years that Iran possesses a biological weapons capability, or at least the capacity to develop one. The State Department’s latest compliance report indicates that Iran “maintains flexibility to use, upon leadership demand, legitimate research underway … to produce lethal biological weapons agents.” An assessment by the Office of the Director of National Intelligence goes further, stating that Iran “very likely aims to continue R&D of chemical and biological agents for offensive purposes.” These assessments, though unclassified, have received limited public attention until now.
The current war dramatically complicates an already serious situation. As command structures become fractured and facilities are struck, the security of dangerous materials is inevitably compromised. Unlike nuclear materials, which are tracked by radiation detectors, or chemical stockpiles, biological agents can be small, portable and capable of spreading independently once released. A small quantity, even a single vial, could pose a significant threat.
Echoes of the Post-Soviet Era
The potential for biological materials to fall into the wrong hands isn’t a new concern. Following the collapse of the Soviet Union, the United States launched the Nunn-Lugar program, investing billions of dollars to secure biological, chemical, and nuclear stockpiles in the newly independent states. This program was successful, in part, because those states were willing partners in the effort. Iran, however, presents a different challenge. It is neither stable nor likely to cooperate in securing its biological capabilities.
These capabilities are embedded within a complex network of military-affiliated universities, research centers linked to the Islamic Revolutionary Guard Corps (IRGC), and dual-use pharmaceutical and biotechnology institutions. According to a report by the Center for Strategic and International Studies, this network makes it difficult to track and secure potential biological weapons materials. Some of these facilities have already been targeted in strikes, and others may be in the future. Critically, the U.S. Currently lacks a reliable inventory of what biological materials were present at these sites, what has been destroyed, and what risks remain.
The Challenge of Detection and Response
The Congressional Research Service has warned that ongoing military operations “may complicate onsite damage assessments and efforts to secure CBRN” – chemical, biological, radiological, and nuclear – materials. In simpler terms, the U.S. May not fully understand the consequences of its strikes, including what materials are now unsecured and where they might end up.
Detecting a deliberate or accidental release of a biological agent would be exceptionally difficult. Current biosurveillance systems are designed to identify known diseases, relying on syndromic surveillance, emergency department reporting, and wastewater analysis. An engineered pathogen, or one previously unknown, could easily evade these systems, circulating for days or weeks before being detected. By the time it appears in emergency rooms, transmission chains may already be established across multiple cities, severely limiting containment options.
the U.S. Strategic National Stockpile has documented gaps in the countermeasures needed to respond to a biological attack. A Government Accountability Office report highlights deficiencies in the availability of medical countermeasures against threat agents that have been on the U.S. Concern list for decades. The research and manufacturing infrastructure to rapidly close these gaps is currently insufficient, and the workforce needed to deploy countermeasures has been shrinking.
Beyond Oil: A Different Kind of Disruption
The consequences of a biological release – whether deliberate or accidental – would be far more disruptive than any oil market shock. The COVID-19 pandemic, caused by a naturally occurring virus that was not engineered for lethality, erased tens of trillions of dollars from the global economy and fundamentally altered daily life for years. A deliberately engineered pathogen, optimized for transmission and virulence, could be exponentially more devastating.
A potential scenario involves a strike damaging a storage or research facility, dispersing materials into the surrounding environment – an unintended consequence that goes unrecognized initially. Alternatively, the chaos of a collapsing command structure could create an opportunity for a small quantity of a dangerous agent to fall into the hands of someone with malicious intent. Even the Iranian government, facing existential military pressure, might consider biological retaliation as a less risky option than conventional defeat.
What Needs to Happen Now
Congress must demand a comprehensive accounting of what is known about Iran’s biological materials – their location and status since the strikes began. More importantly, biological preparedness must be elevated to a national security priority, receiving sustained funding and attention. This is not simply a matter of pandemic response; it requires a dedicated investment in biosurveillance infrastructure, stockpile replenishment, and research and development of countermeasures.
The world has spent decades building treaties, monitoring systems, and institutions to manage the risks of nuclear weapons. For biological threats, the infrastructure is woefully inadequate. The current conflict is exposing this critical deficit. A missile launch is visible; a vial leaving an unsecured facility is not. The focus must shift to addressing this hidden danger before it’s too late.